Vitamin D and the Cardiovascular System

被引:137
作者
Artaza, Jorge N. [1 ,2 ]
Mehrotra, Rajnish [2 ,3 ]
Norris, Keith C. [1 ,2 ,3 ]
机构
[1] Charles R Drew Univ Med & Sci, Los Angeles, CA 90059 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[3] Los Angeles Biomed Res Inst, Torrance, CA USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2009年 / 4卷 / 09期
关键词
LEFT-VENTRICULAR HYPERTROPHY; CHRONIC KIDNEY-DISEASE; D-RECEPTOR; SERUM; 25-HYDROXYVITAMIN-D; CARDIAC-HYPERTROPHY; D DEFICIENCY; SECONDARY HYPERPARATHYROIDISM; 1,25-DIHYDROXYVITAMIN D-3; MYOCARDIAL-INFARCTION; CELL-PROLIFERATION;
D O I
10.2215/CJN.02260409
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Several epidemiologic and clinical studies have suggested that there is a strong association between hypovitaminosis D and cardiovascular disease (CVD). Hypovitaminosis D was reported as a risk factor for increased cardiovascular events among 1739 adult participants in the Framingham Offspring Study. Analysis of more than 13,000 adults in the Third National Health and Nutrition Examination Survey (NHANES III) showed that even though hypovitaminosis D is associated with an increased prevalence of CVD risk factors, its association with all-cause mortality is independent of these risk factors. Importantly, epidemiologic studies suggested that patients who had chronic kidney disease and were treated with activated vitamin D had a survival advantage when compared with those who did not receive treatment with these agents. Mechanistically, emerging data have linked vitamin D administration with improved cardiac function and reduced proteinuria, and hypovitaminosis D is associated with obesity, insulin resistance, and systemic inflammation. Preliminary studies suggested that activated vitamin D inhibits the proliferation of cardiomyoblasts by promoting cell-cycle arrest and enhances the formation of cardiomyotubes without inducing apoptosis. Activated vitamin D has also been shown to attenuate left ventricular dysfunction in animal models and humans. In summary, emerging studies suggest that hypovitaminosis D has emerged as an independent risk factor for all-cause and cardiovascular mortality, reinforcing its importance as a public health problem. There is a need to advance our understanding of the biologic pathways through which vitamin D affects cardiovascular health and to conduct prospective clinical interventions to define precisely the cardioprotective effects of nutritional vitamin D repletion. Clin J Am Soc Nephrol 4: 1515-1522, 2009. doi: 10.2215/CJN.02260409
引用
收藏
页码:1515 / 1522
页数:8
相关论文
共 60 条
[21]   Vitamin D receptor activation and survival in chronic kidney disease [J].
Kovesdy, C. P. ;
Kalantar-Zadeh, K. .
KIDNEY INTERNATIONAL, 2008, 73 (12) :1355-1363
[22]   Association of activated vitamin D treatment and mortality in chronic kidney disease [J].
Kovesdy, Csaba P. ;
Ahmadzadeh, Shahram ;
Anderson, John E. ;
Kalantar-Zadeh, Kamyar .
ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (04) :397-403
[23]   Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease [J].
Levin, A. ;
Bakris, G. L. ;
Molitch, M. ;
Smulders, M. ;
Tian, J. ;
Williams, L. A. ;
Andress, D. L. .
KIDNEY INTERNATIONAL, 2007, 71 (01) :31-38
[24]   The macrophage foam cell as a target for therapeutic intervention [J].
Li, AC ;
Glass, CK .
NATURE MEDICINE, 2002, 8 (11) :1235-1242
[25]  
Li YC, 2002, J CLIN INVEST, V110, P229, DOI [10.1172/JCI200215219, 10.1172/JCI0215219]
[26]   Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response [J].
Liu, PT ;
Stenger, S ;
Li, HY ;
Wenzel, L ;
Tan, BH ;
Krutzik, SR ;
Ochoa, MT ;
Schauber, J ;
Wu, K ;
Meinken, C ;
Kamen, DL ;
Wagner, M ;
Bals, R ;
Steinmeyer, A ;
Zügel, U ;
Gallo, RL ;
Eisenberg, D ;
Hewison, M ;
Hollis, BW ;
Adams, JS ;
Bloom, BR ;
Modlin, RL .
SCIENCE, 2006, 311 (5768) :1770-1773
[27]   Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States - Data from the Third National Health and Nutrition Examination Survey [J].
Martins, David ;
Wolf, Myles ;
Pan, Deyu ;
Zadshir, Ashraf ;
Tareen, Naureen ;
Thadhani, Ravi ;
Felsenfeld, Arnold ;
Levine, Barton ;
Mehrotra, Rajnish ;
Norris, Keith .
ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (11) :1159-1165
[28]   Vitamin D Receptor Activators Can Protect against Vascular Calcification [J].
Mathew, Suresh ;
Lund, Richard J. ;
Chaudhary, Lala R. ;
Geurs, Theresa ;
Hruska, Keith A. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 19 (08) :1509-1519
[29]   25-hydroxyvitamin D levels and the risk of mortality in the general population [J].
Melamed, Michal L. ;
Michos, Erin D. ;
Post, Wendy ;
Astor, Brad .
ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (15) :1629-1637
[30]   Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease - Results from NHANES 2001 to 2004 [J].
Melamed, Michal L. ;
Muntner, Paul ;
Michos, Erin D. ;
Uribarri, Jaime ;
Weber, Collin ;
Sharma, Jyotirmay ;
Raggi, Paolo .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (06) :1179-1185